Sinew Pharma Inc. (TPEX:6634)
Taiwan
· Delayed Price · Currency is TWD 33.70
-0.70 (-2.08%)
Mar 10, 2026, 1:39 PM CST
Sinew Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | - | - | 0.33 | 6.23 | 0.46 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | -94.73% | 1248.27% | - | Upgrade
|
| Cost of Revenue | - | - | - | 0.04 | 1.14 | 0.14 | Upgrade
|
| Gross Profit | - | - | - | 0.29 | 5.09 | 0.32 | Upgrade
|
| Selling, General & Admin | 40.28 | 36.95 | 34.75 | 34.1 | 26.77 | 17.73 | Upgrade
|
| Research & Development | 119.39 | 131.91 | 151.51 | 114.62 | 72.75 | 66.71 | Upgrade
|
| Operating Expenses | 159.67 | 168.86 | 186.25 | 148.72 | 99.51 | 84.43 | Upgrade
|
| Operating Income | -159.67 | -168.86 | -186.25 | -148.43 | -94.42 | -84.11 | Upgrade
|
| Interest Expense | -0.2 | -0.41 | -0.78 | -0.28 | -0.15 | -0.27 | Upgrade
|
| Interest & Investment Income | 16.5 | 16.66 | 16.03 | 8.37 | 2.95 | 2.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.46 | 2.25 | 0.08 | 0.15 | 0.04 | 0 | Upgrade
|
| Pretax Income | -141.91 | -150.37 | -170.92 | -140.18 | -91.58 | -82.01 | Upgrade
|
| Net Income | -141.91 | -150.37 | -170.92 | -140.18 | -91.58 | -82.01 | Upgrade
|
| Net Income to Common | -141.91 | -150.37 | -170.92 | -140.18 | -91.58 | -82.01 | Upgrade
|
| Shares Outstanding (Basic) | 71 | 71 | 70 | 69 | 59 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 71 | 71 | 70 | 69 | 59 | 50 | Upgrade
|
| Shares Change (YoY) | 0.12% | 1.21% | 1.68% | 16.47% | 19.41% | 30.28% | Upgrade
|
| EPS (Basic) | -1.99 | -2.11 | -2.43 | -2.02 | -1.54 | -1.65 | Upgrade
|
| EPS (Diluted) | -1.99 | -2.11 | -2.43 | -2.02 | -1.54 | -1.65 | Upgrade
|
| Free Cash Flow | -97.47 | -106.26 | -125.26 | -98.99 | -59.5 | -61.06 | Upgrade
|
| Free Cash Flow Per Share | -1.37 | -1.49 | -1.78 | -1.43 | -1.00 | -1.23 | Upgrade
|
| Gross Margin | - | - | - | 88.41% | 81.75% | 70.13% | Upgrade
|
| Operating Margin | - | - | - | -45252.44% | -1515.81% | -18204.76% | Upgrade
|
| Profit Margin | - | - | - | -42737.81% | -1470.14% | -17751.30% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -30178.66% | -955.19% | -13217.10% | Upgrade
|
| EBITDA | -137.49 | -144.98 | -163.63 | -128.29 | -73.88 | -64.41 | Upgrade
|
| D&A For EBITDA | 22.18 | 23.88 | 22.62 | 20.13 | 20.55 | 19.7 | Upgrade
|
| EBIT | -159.67 | -168.86 | -186.25 | -148.43 | -94.42 | -84.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.